Effects from statin treatment on ADRD biomarkers have shown divergent results: No group differences were seen in CSF Aβ42 or tau between simvastatin treatment and placebo in cognitively normal [197] or pre-dementia stage [198]. This evidence concerns the gene MAPT and dementia.